#USA #IceCure Medical #Cryoablation #ProSense #CA,USA

IceCure Medical Reports 70% Growth in Cryoablation Systems

IceCure Medical Ltd., a leading developer of minimally invasive cryoablation technology, has announced a staggering 70% increase in its active U.S. installation base of ProSense® systems. This surge follows the company’s recent FDA marketing authorization in October 2025 and reflects not only escalating commercial adoption but also a significant rise in physician demand across the country.

The ProSense® device, which freezes and destroys tumors, provides a viable non-surgical option specifically designed for women aged 70 and older diagnosed with low-risk breast cancer. This includes patients for whom surgical procedures may not be appropriate. As the medical field embraces innovative treatment approaches, IceCure’s technology offers new hope for affected patients.

Key Drivers of Growth

The surge in installations can be attributed to several key factors:
1. FDA Approval: The significant milestone of receiving marketing authorization from the FDA has marked a turning point for IceCure, giving healthcare providers the confidence to adopt this novel treatment option.
2. Expanding Clinical Acceptance: The American Society of Breast Surgeons (ASBrS) has recently recommended cryoablation as a viable local treatment option for low-risk breast cancer patients. This endorsement demonstrates a growing recognition of cryoablation's efficacy among healthcare professionals.
3. Increased Patient Awareness: With increased media attention, including coverage by Reuters and local news segments aired across numerous CBS and CW-affiliated stations, patients are becoming more informed about available treatment alternatives, thereby opening doors for better health discussions with their healthcare providers.

Expanding Footprint

The company has been actively installing ProSense® systems in numerous clinics and hospitals nationwide. In cities such as Los Angeles, New York, and Atlanta, among others, healthcare facilities are beginning to integrate this innovative technology into their treatment methodologies. The proactive participation of IceCure in breast health conferences throughout the year has resulted in an impressive uptick in sales leads generated, symbolizing increased interest from both physicians and healthcare professionals.

IceCure’s CEO, Eyal Shamir, expressed optimism about the future, stating, “With growing physician interest, expanding clinical acceptance, and increased patient awareness, we believe we remain in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S.” He emphasized the company's commitment to supporting physicians through training, education, and improving patient access to ProSense® systems.

The Future of Cryoablation

With the latest developments, IceCure Medical is poised to make further strides in the field of breast cancer treatment. As the ProSense® system continues to gain traction in the clinical landscape, its ability to offer a minimally invasive alternative will provide patients with new options for effective cancer care. IceCure Medical is dedicated to advancing this technology and increasing its presence in the healthcare community to ensure that more patients have access to these potentially life-saving procedures.

As the company continues to expand its offerings and educate both patients and providers, the outlook for the use of cryoablation as a primary treatment option for breast cancer is becoming increasingly promising. IceCure Medical remains at the forefront of this transformation in cancer treatment, demonstrating innovative approaches to enhance patient outcomes and overall healthcare experiences.